Daily Cosmetic Research Analysis
Analyzed 16 papers and selected 3 impactful papers.
Summary
Analyzed 16 papers and selected 3 impactful articles.
Selected Articles
1. Corylin promotes healthy aging via RAGA-mTOR suppression and sex-dependent activation of SIRT3.
Mid-life Corylin improved metabolic and physical function and extended female mouse lifespan by 11.9%, with a 33% higher survival at 125 weeks. Multi-omics linked Corylin to RAGA-mediated mTOR suppression and restoration of SIRT3 and energy programs in females, explaining sex-dependent benefits.
Impact: Identifies a small molecule geroprotector with sex-specific efficacy and a defined RAGA-mTOR/SIRT3 mechanism, advancing translational aging biology. The mechanistic clarity provides targets for future clinical development.
Clinical Implications: Suggests a candidate pathway (RAGA-mTOR and SIRT3) for geroprotective interventions and supports sex-specific trial design. Potential applications include metabolic and musculoskeletal aging and possibly dermatologic anti-aging strategies.
Key Findings
- Corylin extended median lifespan by 11.9% in female mice with 33% higher survival at 125 weeks; no similar benefit in males.
- Integrated multi-omics linked Corylin to suppression of mTOR signaling via direct interaction with RAGA.
- Corylin restored SIRT3 protein levels and energy metabolism programs in females, aligning with sex-dependent benefits.
Methodological Strengths
- Multi-omics across multiple tissues with in vivo functional and lifespan endpoints
- Mechanistic evidence including direct interaction with RAGA supporting target engagement
Limitations
- Preclinical mouse study; human translatability and safety remain unknown
- Sex-specific benefit limited to females; mechanisms in males unresolved
Future Directions: Evaluate pharmacokinetics, safety, and biomarkers in humans; test dermatologic and musculoskeletal endpoints; dissect sex-specific signaling to optimize personalized geroprotection.
Aging is accompanied by progressive physiological decline and an increased risk of chronic disease, motivating the search for interventions that promote healthy longevity. We found that mid-life administration of Corylin, a flavonoid derived from Psoralea corylifolia, improves metabolic function, muscle integrity, and physical performance in mice maintained on a standard diet. Corylin significantly extends median lifespan in female mice, with an 11.9% increase and a 33% higher survival rate at 125 weeks, whereas no comparable benefit is observed in males. Here, we show that integrated multi-omics analyses across multiple tissues reveal coordinated age-associated molecular changes modulated by Corylin. These analyses link Corylin treatment to suppression of mechanistic target of rapamycin signaling, which is further supported by direct interaction between Corylin and Ras-related GTP-binding protein A. In addition, Corylin restores sirtuin 3 protein levels and energy-associated metabolic programs in female mice, providing mechanistic insight into sex-dependent longevity benefits.
2. Tri-APBI: Single Institution Phase I/II Prospective Clinical Trial of Three Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer.
In 75 low-risk stage 0–I breast cancer patients, a 3-fraction APBI regimen over 2–3 days yielded a 2.6% ipsilateral recurrence at 49 months with no grade ≥2 toxicity. Cosmesis remained good-to-excellent by both subjective ratings and pBRA, with minimal QoL impact.
Impact: Demonstrates feasibility of an ultra-hypofractionated APBI schedule with excellent cosmetic outcomes and low toxicity, potentially reducing treatment burden while maintaining control.
Clinical Implications: Supports consideration of 3-fraction APBI in selected low-risk patients to shorten treatment while preserving cosmesis. Requires validation in multi-institutional and randomized settings before guideline changes.
Key Findings
- Three-fraction APBI delivered via EBRT or HDR over 2–3 days achieved 2.6% ipsilateral recurrence at 49 months with no grade ≥2 toxicity.
- Cosmesis remained good-to-excellent (patient 94%→91%, physician 99%→98%); quantitative pBRA did not worsen from baseline.
- QoL largely unchanged; only transient increases in breast symptom burden (48–60 months) and sexual functioning (36 months).
Methodological Strengths
- Prospective phase I/II design with both subjective and quantitative cosmesis (pBRA) assessments
- Median 49-month follow-up with clear reporting of recurrence and toxicity
Limitations
- Single-institution, nonrandomized design with physician-selected modality
- Long-term oncologic efficacy beyond 4 years remains to be established
Future Directions: Multi-institutional randomized trials comparing Tri-APBI to standard schedules, with longer follow-up and patient-reported outcomes, to confirm efficacy and cosmesis.
PURPOSE: To report safety, feasibility, toxicity, cosmetic and quality-of-life (QoL) outcomes of a single institutional prospective phase I/II clinical trial evaluating a novel three-fraction accelerated partial breast irradiation (Tri-APBI) regimen. METHODS AND MATERIALS: From August 2018 to March 2021, 75 patients with low-risk hormone sensitive, HER2 negative breast cancer were enrolled on Tri-APBI, delivered with high dose rate (HDR) brachytherapy (22.5 Gy in 3 fractions) or external beam radiation therapy (EBRT) (25.5 Gy in 3 fractions) over 2-3 days. Modality was chosen by the treating physician. Planning target volume (PTV) for all patients was created using a 1-cm expansion of breast tissue around the surgical bed limited by 0.5 cm from the skin surface. RESULTS: Stage I disease was present in 79%, while the remainder had DCIS. Tri-APBI was delivered with EBRT in 45 patients (60%) and HDR in 30 (40%). At a median follow-up of 49 months (IQR 42 - 55 months), there were two ipsilateral breast tumor recurrences (IBTR), cumulatively 2.6%, both successfully salvaged. There were no axillary or distant recurrences. There was no CTCAEv4.0 grade 2+ toxicity observed. Good-to-excellent pretreatment cosmesis was present in 94% and 99% by patient and physician rating, respectively, and in 91% and 98% at latest follow-up. Quantitative cosmesis assessed by percentage of breast retraction assessment (pBRA) showed that breast asymmetry did not worsen compared to pre-treatment, with a baseline mean pBRA of 8.1% (CI 4.1 - 12) and a 24-month mean pBRA of 6.1% (CI 4.0 - 8.1). Tri-APBI did not negatively impact most domains of patient-reported quality of life, except breast symptom burden at 48 and 60 months and sexual functioning at 36 months only. CONCLUSIONS: Tri-APBI as delivered with EBRT or HDR in this trial was feasible and well-tolerated, with low IBTR rates at 4 years and minimal impact on patient-reported quality of life, qualitative, and quantitative cosmesis. Further follow-up is needed to evaluate long-term oncologic efficacy.
3. Surface-driven endocrine activity of nanoplastics: polymer- and size-dependent estrogen and androgen receptors modulation without steroidogenesis perturbation.
Across OECD-aligned assays, PE and PP nanoplastics modulated ER/AR activity in a size- and polymer-dependent manner without altering steroidogenesis, and mixtures potentiated receptor responses. Findings implicate receptor-proximal, surface-driven mechanisms and prioritize polymers/sizes for risk assessment relevant to cosmetics exposure.
Impact: Provides polymer- and size-resolved endocrine hazard evidence using OECD TGs and reveals mixture-driven potentiation, informing safer-by-design materials and regulatory screening beyond polystyrene surrogates.
Clinical Implications: Guides exposure monitoring and ingredient selection in consumer products by flagging PE/PP nanoplastics and mixture contexts for priority assessment; supports development of safer formulations in cosmetics.
Key Findings
- PE (350 nm) and PP (180 nm) nanoplastics acted as ER agonists; PP (50 and 180 nm) and PE (350 nm) antagonized AR, while PS and PET showed no single-material activity.
- Several polymer-matched mixtures elicited ER/AR responses even when individual constituents were inactive, indicating mixture-dependent potentiation.
- No cytotoxicity from 0.1–10 mg/L and no OECD decision-rule trigger for altered steroidogenesis in H295R despite sporadic intermediate changes.
Methodological Strengths
- Use of OECD-aligned TG 455/456/458 across multiple cell models with factorial polymer/size design
- Inclusion of polymer-matched mixtures to probe interaction effects often overlooked in single-material testing
Limitations
- In vitro assays without in vivo validation; human exposure-dose relevance remains uncertain
- Tested concentration ranges may not fully reflect chronic low-dose real-world exposures
Future Directions: Translate to in vivo exposure models and human biomonitoring; define dose–response at realistic exposure levels; integrate mixture modeling into regulatory risk assessment for cosmetics.
Growing production and use of plastics have led to significant environmental pollution including the formation and accumulation of plastic nanoparticles (PNPs). Due to their small size, PNPs easily enter the human food chain; however, humans are also exposed to plastics through other consumer pathways, such as the use of cosmetic products. Despite considerable efforts to investigate the potential adverse effects of plastics, their impact on human health is not yet fully understood. In particular, endocrine disruption has emerged as a potential mechanism underlying reported reproductive and hormonal effects of micro- and nanoplastics. We applied an OECD-aligned in vitro test guidelines (TGs) to a factorial panel of eight PNPs spanning four common polymers (polystyrene (PS), polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET)) with size-resolved materials and polymer-matched mixtures. Thus, estrogen receptor a (ERα) transactivation (TG 455), androgen receptor (AR) transactivation (TG 458, antagonist mode), and H295R steroidogenesis (TG 456) assays were performed using HeLa-9903, AR-EcoScreen GR KO M1, and NCI-H295R cell models, respectively. Across 0.1-10 mg L⁻¹, no cytotoxicity was observed. PENPs (350 nm) and PPNPs (180 nm) acted as ER agonists, whereas PPNPs (50 and 180 nm) and PENPs (350 nm) antagonized AR; PSNPs and PETNPs showed no activity when tested individually. Notably, several mixtures elicited ER and AR responses even when constituent singles were inactive, indicating mixture-dependent potentiation. In contrast, the H295R assay did not meet the OECD decision rule for altered steroidogenesis: sporadic shifts in pathway intermediates did not propagate to estradiol or testosterone. Altogether, the data support a surface- and polymer-dependent, receptor-proximal mode of action for PNPs and highlight mixture effects as a critical, underappreciated driver. These results move endocrine hazard evaluation beyond polystyrene surrogates and provide decision-useful guidance on which polymers/sizes and mixture contexts merit priority in exposure monitoring and risk assessment.